You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Exelixis reported third-quarter 2026 total revenues of approximately $659 million and global Cabo franchise net product revenue of $818 million. ZANSA’s PDUFA action date is March 3rd, 2027, and Stellar 304 top-line results are expected in the first quarter next year.
Exelixis reported third-quarter 2026 net product revenues of $604.9 million, up from $542.9 million, while the FDA extended the zanzalintinib metastatic colorectal cancer NDA review to a March 3, 2027 target action date after a major amendment.
Exelixis reported third-quarter 2026 total revenues of $658.7 million and GAAP diluted EPS of $0.85, while advancing zanzalintinib trials and awaiting an FDA decision with a March 3, 2027 target action date.
